Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 52 of the 76 sources its claims cite were checked for support.
Abstract
The mechanism of action of eprenetapopt (APR-246, PRIMA-1 MET ) as an anticancer agent remains unresolved, although the clinical development of eprenetapopt focuses on its reported mechanism of action as a mutant-p53 reactivator. Using unbiased approaches, this study demonstrates that eprenetapopt depletes cellular antioxidant glutathione levels by increasing its turnover, triggering a nonapoptotic, iron-dependent form of cell death known as ferroptosis. Deficiency in genes responsible for supplying cancer cells with the substrates for de novo glutathione synthesis ( SLC7A11 , SHMT2 , and MTHFD1L ), as well as the enzymes required to synthesize glutathione ( GCLC and GCLM ), augments the activity of eprenetapopt. Eprenetapopt also inhibits iron-sulfur cluster biogenesis by limiting the cysteine desulfurase activity of NFS1, which potentiates ferroptosis and may restrict cellular proliferation. The combination of eprenetapopt with dietary serine and glycine restriction synergizes to inhibit esophageal xenograft tumor growth. These findings reframe the canonical view of eprenetapopt from a mutant-p53 reactivator to a ferroptosis inducer.
Overview
CoChat Summary
TL;DR
Eprenetapopt (APR-246) depletes glutathione by increasing its turnover, triggers iron-dependent nonapoptotic ferroptosis, and inhibits NFS1 cysteine desulfurase rather than acting primarily as a mutant-p53 reactivator. Combining eprenetapopt with dietary serine and glycine restriction synergizes to inhibit esophageal tumor growth in vivo.
Key findings
- Genome-wide CRISPR screens in OACM5.1 cells identified GSH synthesis genes as central modulators: SLC7A11 and GCLM dropped out in CRISPRko, GCLC was top enriched in CRISPRa, and mito-1C genes SHMT2 and MTHFD1L plus ESD also sensitized cells to eprenetapopt; TP53 and apoptotic machinery were not identified.
- Eprenetapopt decreased reduced GSH without increasing GSSG, and 13C2-cystine tracing showed increased incorporation into glutamylcysteine, GSH, GSSG, and cysteinylglycine, with MQ-GSH and MQ-cysteine adducts detected, indicating increased GSH turnover/degradation rather than blocked de novo synthesis.
- Eprenetapopt-induced cell death was rescued by ferrostatin-1 and ciclopirox olamine but not zVAD-FMK in H1299 and FLO-1 cells, and apoptosis-deficient MC38 cells lacking Bax/Bak/Bid/Casp3/Casp7 were still killed, supporting ferroptosis.
- MQ inhibited NFS1 cysteine desulfurase activity in cell-free and 293T assays and reduced aconitase activity; dietary serine/glycine restriction plus eprenetapopt (100 mg/kg daily) inhibited primary tumor growth, delayed metastasis, and prolonged survival in FLO-1 LM mice, and limited esophageal adenocarcinoma PDX growth.
Methods
- Multiomics approach: genome-wide CRISPRko (Brunello, 76,441 sgRNAs) and CRISPRa (Calabrese, 56,762 sgRNAs) screens in OACM5.1 esophageal cancer cells; untargeted LC-MS metabolomics and label-free quantitative proteomics after 50 μM eprenetapopt for 12 hours; DepMap/CTRPv2 correlation analyses.
- Cell death and mechanism assays: PI uptake/IncuCyte and alamarBlue viability; ferroptosis rescue with Fer-1, CPX, zVAD-FMK, or NAC; apoptosis-resistant MC38 cells; NFS1 cysteine desulfurase assays measuring H2S release or 35S-cysteine persulfide formation; aconitase activity assays.
- In vivo models: FLO-1 LM cell line xenografts and esophageal adenocarcinoma PDXs in NSG mice, randomized to normal or serine/glycine-free diet and eprenetapopt (100 mg/kg daily) or vehicle; tumor growth, bioluminescence metastasis, and survival analyzed with t tests, ANOVA, and log-rank tests.
Limitations
- The paper states that the precise mechanism by which eprenetapopt depletes GSH and inhibits NFS1 remains to be determined.
- Evident from the text: the CRISPRa screen was performed with n = 1, some assays had n = 1 or n = 2, and no power analyses were performed to determine sample size before experimentation.
- Evident from the text: eprenetapopt monotherapy failed to inhibit primary tumor growth or metastatic spread in the FLO-1 LM model, and efficacy in culture was limited by high cell confluency and low O2 levels; in vivo synergy was shown only in esophageal cancer models.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1. Multiomics strategy to determine the MoA of eprenetapopt. (A) Schematic diagram showing a strategy to determine the MoA of eprenetapopt. (B) Heatmap of sensitivity to eprenetapopt analog (APR-017). Cancer lineages are ordered by sensitivity determined by delta median, area under the curve (AUC) of compound activity. Percentages denote the frequency of TP53 mutations in each lineage. CNS, central nervous system; PNS, peripheral nervous system. (C) Schematic showing the workflow for the CRISPRko and CRISPRa screens in OACM5.1 cells. (D) MAGeCK scores (negative indicating dropout and positive indicating “enrichment”) from CRISPR screens, plotted in order of magnitude. (E) Cellular metabolic activity measured by alamarBlue as a surrogate readout for cell viability following 72-hour exposure with eprenetapopt at indicated doses in cells transduced with individual sgRNA targeting identified hits. Heatmap represents the change in GI50 (dose where 50% growth inhibition is achieved) relative to control. (F) Fisher’s transformed z-scored Pearson correlation strength of gene dependency from the DepMap database with eprenetapopt analog (APR-017) sensitivity data from CTRPv2, plotted in order of magnitude. (G) Comparison of CRISPR screens and DepMap gene dependency data shows overlay of glutamate-cysteine ligase units (GCLC and GCLM). Plot is representing the rank of top hits (ordered by dropout in CRISPRko, by enrichment in CRISPRa, and by positive correlations in DepMap). Dashed lines indicate overlap of top 50 ranked genes. (H) Changes in polar metabolites determined by untargeted liquid chromatography–mass spectrometry (LC-MS) metabolomics and (I) proteins determined by label-free quantitative proteomics in OACM5.1 cells following treatment with 50 μM eprenetapopt for 12 hours compared to vehicle. Dotted lines indicate significance cutoffs {P < 0.05, |log2[fold change (FC)]| > 0.5}. Two-tailed unpaired t test (H and I). Error bars = SEM. (D) n = 2 for CRISPRko, n = 1 for CRISPRa, (E) n = 3 to 4, (H) n = 6, and (I) n = 4. See also fig. S1.](https://figures.cochat.ai/paper-figures/95778abe2c7e4affaca89228901ced2a/eprenetapopt-triggers-ferroptosis-inhibits-nfs1-cysteine-desulfurase-and-figure-1.jpg)

![Fig. 3. Eprenetapopt triggers ferroptosis. (A) Percentage (%) of dead cells [as determined by % PI+ cells] and percentage of cell confluency following treatment for 24 hours with 50 μM eprenetapopt with or without 50 μM zVAD-FMK (pan-caspase inhibitor), 12.5 μM Fer-1 (lipophilic antioxidant), 6.25 μM CPX (iron chelator), or 2.5 mM NAC (cysteine supplement) in H1299 (left) and FLO-1 cells (right). (B) Representative merged phase and red channel images of results from (A) acquired on IncuCyte. (C) Percentage of cell death determined by PI uptake following 24-hour treatment with 50 μM eprenetapopt in H1299 cells at indicated cell densities. (D) Immunoblot of Bax, Bak, Bid, Casp3, and Casp7 illustrating the efficiency of CRISPR editing in MC38 cells. (E) Left: Cell death in MC38 wild-type (WT) and apoptosis-deficient (Apop KO) cells following 24-hour treatment with 50 μM eprenetapopt or 12.5 μM STS. Right: Cellular metabolic activity measured by alamarBlue as a surrogate readout for cell viability following 72-hour exposure with eprenetapopt at indicated doses in wild-type and apoptosis-deficient MC38 cells. Two-way t test (A and E). *P < 0.05, **P < 0.01, and ****P < 0.0001. (A) n = 2 to 3, (D) n = 2, representative blots shown, and (E) n = 3. See also fig. S3 and movie S1.](https://figures.cochat.ai/paper-figures/d428f807eb644046bf7a14de31ff0dc3/eprenetapopt-triggers-ferroptosis-inhibits-nfs1-cysteine-desulfurase-and-figure-3.jpg)

Verification
Claims the paper makes
35 Valid · 1 Not valid · 14 Not checked · 87 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, in contradiction to previous investigations (9), we found that eprenetapopt treatment decreases the level of glutathionylation in cells (fig. S2K)”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > RESULTS > Eprenetapopt and mito-1C metabolism
What the sources say
- Supportedcites [9] L. Haffo, J. Lu, V. J. N. Bykov, S. S. Martin, X. Ren, L. Coppo, K. G. Wiman, A. Holmgren, Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246. Sci. Rep. 8, 12671 (2018). 30140002 PMC6107631 source
The citation is attached to “previous investigations,” not to the citing authors’ finding of a decrease. In the Results section (“Total glutathionylation in Saos-2 and Saos-2-His-273 cells”), the source reports that glutathionylation increased with increasing APR-246 concentration, establishing the contrast the citing sentence describes. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This model is in keeping with our prior work, and confirmed by others (7, 8, 20), demonstrating that inhibiting cystine uptake with erastin or sulfasalazine synergizes with eprenetapopt both in vitro and in vivo.”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > RESULTS > Eprenetapopt and mito-1C metabolism
What the sources say
- Partly supportedcites [7] S. Ceder, S. E. Eriksson, E. H. Cheteh, S. Dawar, M. C. Benitez, V. J. N. Bykov, K. M. Fujihara, M. Grandin, X. Li, S. Ramm, C. Behrenbruch, K. J. Simpson, F. Hollande, L. Abrahmsen, N. J. Clemons, K. G. Wiman, A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death. EMBO Mol. Med. 13, e10852 (2021). 33314700 PMC7863383 sourceExperimental — accuracy not yet measured
The Discussion (page not available in our copy) says APR-246 synergizes with the cystine-uptake inhibitor sulfasalazine in vitro and reports an in vivo finding from Liu et al. (2017). The cell-culture results also describe sulfasalazine synergy. The passages do not support the erastin part of the claim. (LLM, conf=0.88)
- Partly supportedcites [8] D. S. Liu, C. P. Duong, S. Haupt, K. G. Montgomery, C. M. House, W. J. Azar, H. B. Pearson, O. M. Fisher, M. Read, G. R. Guerra, Y. Haupt, C. Cullinane, K. G. Wiman, L. Abrahmsen, W. A. Phillips, N. J. Clemons, Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat. Commun. 8, 14844 (2017). 28348409 PMC5379068 sourceExperimental — accuracy not yet measured
The Results section reports that both erastin and sulfasalazine (SAS) strongly synergized with APR-246 in cancer cells. In the in vivo xenograft experiments, it reports greater antitumour activity for SAS plus APR-246 than for either agent alone, but does not report an erastin combination in vivo. Thus the claim’s in vivo extension to both drugs is not supported by this paper. (LLM, conf=0.88)
- Partly supportedcites [20] R. Birsen, C. Larrue, J. Decroocq, N. Johnson, N. Guiraud, M. Gotanegre, L. Cantero-Aguilar, E. Grignano, T. Huynh, M. Fontenay, O. Kosmider, P. Mayeux, N. Chapuis, J. E. Sarry, J. Tamburini, D. Bouscary, APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica 107, 403– 416 (2022). 33406814 PMC8804578 sourceExperimental — accuracy not yet measured
The Results section on cystine uptake reports that erastin synergized with APR-246 in AML cell lines and primary samples in vitro. The in vivo Results section reports enhanced activity from combining APR-246 with genetic SLC7A11 knockdown, not erastin or sulfasalazine. Our copy does not report sulfasalazine synergy. (LLM, conf=0.89)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, two mito-1C metabolism genes, SHMT2 and MTHFD1L, and the S-formylglutathione hydrolase gene, ESD, involved in GSH-mediated formaldehyde detoxification (12) were identified in the CRISPRko screen.”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > RESULTS > Multiomics strategy to determine the MoA of eprenetapopt
What the sources say
- Partly supportedcites [12] G. Burgos-Barragan, N. Wit, J. Meiser, F. A. Dingler, M. Pietzke, L. Mulderrig, L. B. Pontel, I. V. Rosado, T. F. Brewer, R. L. Cordell, P. S. Monks, C. J. Chang, A. Vazquez, K. J. Patel, Mammals divert endogenous genotoxic formaldehyde into one-carbon metabolism. Nature 548, 549– 554 (2017). 28813411 PMC5714256 sourceExperimental — accuracy not yet measured
The section ‘ADH5 fuels the growth of 1C-cycle-deficient cells’ describes S-formylglutathione hydrolase regenerating GSH as part of a formaldehyde-detoxification route. It does not identify that hydrolase as ESD. The citation is attached to the detoxification clause; this source does not report the claimed identification of SHMT2, MTHFD1L and ESD in a CRISPR knockout screen. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In our prior work, we showed that eprenetapopt induces lipid peroxidation following GSH depletion (8).”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > RESULTS > Eprenetapopt triggers ferroptosis
What the sources say
- Supportedcites [8] D. S. Liu, C. P. Duong, S. Haupt, K. G. Montgomery, C. M. House, W. J. Azar, H. B. Pearson, O. M. Fisher, M. Read, G. R. Guerra, Y. Haupt, C. Cullinane, K. G. Wiman, L. Abrahmsen, W. A. Phillips, N. J. Clemons, Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation. Nat. Commun. 8, 14844 (2017). 28348409 PMC5379068 source
The Results section, “APR-246 triggers lipid peroxidation through depleting GSH” (page unavailable), reports that APR-246-induced GSH depletion leads to lipid peroxidation. The Discussion states the same mechanism directly; the paper uses the name APR-246 for eprenetapopt. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“eprenetapopt is the first compound to reach a phase 3 clinical trial where triggering ferroptosis is central to its anticancer efficacy.”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > DISCUSSION
What the sources say
- Could not verifycites [37] S. J. Dixon, D. N. Patel, M. Welsch, R. Skouta, E. D. Lee, M. Hayano, A. G. Thomas, C. E. Gleason, N. P. Tatonetti, B. S. Slusher, B. R. Stockwell, Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 3, e02523 (2014). 24844246 PMC4054777 sourceExperimental — accuracy not yet measured
The Results sections on erastin analogs and sorafenib discuss ferroptosis in cancer cells and potential clinical use, but not eprenetapopt. Searches for eprenetapopt, APR-246, and phase 3 trials found no passage establishing that eprenetapopt reached such a trial or that ferroptosis is central to its anticancer efficacy. The cited paper's copy therefore does not address the attributed claim. (LLM, conf=0.76)
- Could not verifycites [21] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht, R. Skouta, E. M. Zaitsev, C. E. Gleason, D. N. Patel, A. J. Bauer, A. M. Cantley, W. S. Yang, B. Morrison III, B. R. Stockwell, Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149, 1060– 1072 (2012). 22632970 PMC3367386 sourceExperimental — accuracy not yet measured
The Abstract and Discussion describe ferroptosis in cancer cells and discuss erastin, RSL3, and other experimental compounds. Searches for eprenetapopt and phase 3 clinical trials found no passage addressing that drug, its trial status, or its mechanism of anticancer efficacy; page numbers were not available in our copy. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [38] J. Du, T. Wang, Y. Li, Y. Zhou, X. Wang, X. Yu, X. Ren, Y. An, Y. Wu, W. Sun, W. Fan, Q. Zhu, Y. Wang, X. Tong, DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic. Biol. Med. 131, 356– 369 (2019). 30557609 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 17 with their cited sources checked
Create a free account to see all 137 claims and every source verdict.
- Probably not a substantial claim. 30
- It may state two separate claims as one. 33
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > INTRODUCTION
“Recent results from two phase 2 clinical trials in TP53-mutated MDS, combining eprenetapopt with standard-of-care azacitidine, reported rates of complete remission (CR) of ~50% (3, 4).”
§ Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction > DISCUSSION
“Both phase 1 clinical trials demonstrated that patients who responded to eprenetapopt and azacitidine had significantly improved overall survival compared to nonresponders (3, 4)”
Citations
Cites
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691 · cited 2×
“Ferroptosis is a form of nonapoptotic cell death characterized by the induction and accumulation of toxic lipid membrane peroxidation catalyzed by iron ( 21 ).”
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“1 cells expressing Cas9-mCherry with the Brunello genome-wide CRISPR knockout (CRISPRko) library ( 10 ) and challenged these cells with a sublethal dose of epreneta-popt for 8 days (Fig.”
Ferroptosis as a p53-mediated activity during tumour suppression
Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · cited 1×
“Further, while previous reports have indicated that p53 activation may be involved in triggering ferroptosis in cancer cells ( 36 ), p53-null cancer cells undergo ferroptosis in response to eprenetapopt treatment, demonstrating that p53 reactivation is dispensable for ferroptosis induced by…”
Broadening horizons: the role of ferroptosis in cancer
Chen, X., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00462-0 · Cited by 2,897 · cited 1×
“…37 ), sulfasala-zine ( 21 ), artemisinin ( 38 ), and statins, as well as conventional chemotherapy, immune checkpoint inhibitors, and radiotherapy ( 39 ), have demonstrated capacity to induce or enhance sensitivity to ferroptosis, eprenetapopt is the first compound to reach a phase 3 clinical…”
Role of Mitochondria in Ferroptosis
Gao, M., Yi, J., Zhu, J., Minikes, A. M., Monian, P., Thompson, C. B., & Jiang, X. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.042 · Cited by 2,120 · cited 1×
“This is because ferroptosis induced by sustained cystine deprivation or erastin treatment perturbs cell proliferation beyond the induction lipid peroxidation ( 22 ).”
Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., Gleason, C. E., Tatonetti, N. P., Slusher, B. S., et al. (2014) · eLife · doi:10.7554/elife.02523 · Cited by 2,088 · cited 1×
“While other clinical compounds including sorafenib ( 37 ), sulfasala-zine ( 21 ), artemisinin ( 38 ), and statins, as well as conventional chemotherapy, immune checkpoint inhibitors, and radiotherapy ( 39 ), have demonstrated capacity to induce or enhance sensitivity to ferroptosis, eprenetapopt is…”
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011 · cited 1×
“Hematological and neurological toxicities, as well as impaired renal function, have been reported in patients receiving eprene-tapopt ( 3 , 4 ), which is in line with reports demonstrating high sensitivity to ferroptosis among mesenchymal-derived tissues ( 41 ).”
Griffith, O. W., & Meister, A. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35980-5 · Cited by 1,683 · cited 1×
“Furthermore, eprenetapopt may be unique, triggering an increase in turnover of GSH rather than restraining de novo GSH synthesis, as imposed by erastin through its inhibition of cystine uptake or by l -buthionine sulfoximine through inhibition of glutamate-cysteine ligase ( 40 ).”
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
Haferlach, T., Nagata, Y., Grossmann, V, Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., Kon, A., Alpermann, T., et al. (2014) · Leukemia · doi:10.1038/leu.2013.336 · Cited by 1,532
Cysteine depletion induces pancreatic tumor ferroptosis in mice
Badgley, M. A., Kremer, D. M., Maurer, H. C., DelGiorno, K. E., Lee, H.-J., Purohit, V., Sagalovskiy, I. R., Ma, A., Kapilian, J., Firl, C. E. M., et al. (2020) · Science · doi:10.1126/science.aaw9872 · Cited by 1,294 · cited 1×
“Reflecting on recent reports suggesting that depletion of CoA contributes to the induction of ferroptosis by erastin ( 25 , 26 ), we first referred to our metabolomics dataset (Fig.”
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“…of pathways independent of p53, 401 – 404 such as downregulating glutathione concentrations in tumor cells, 405,406 regulating oxidation-reduction homeostasis 407 – 409 in tumor cells to trigger ferroptosis, 410 – 412 and inducing endoplasmic reticulum stress 413 or unfolded protein responses.”
BackgroundRecent advances in targeted therapies in acute myeloid leukemia
Bhansali, R. S., Pratz, K. W., & Lai, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01424-6 · Cited by 275
“However, its mechanism may also target other synergistic pathways which can drive p53-independent cell death including modulation of cellular redox [156, 157] and increasing glutathione turnover, leading to ferroptosis [158].”
BackgroundFerroptosis: when metabolism meets cell death
Zheng, J., & Conrad, M. (2025) · Physiological Reviews · doi:10.1152/physrev.00031.2024 · Cited by 246
Exploiting ferroptosis vulnerabilities in cancer
Nakamura, T., & Conrad, M. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01425-8 · Cited by 159
“Eprenetapopt, which is in phase 3 clinical trials, can deplete GSH to induce ferroptosis 81,82 and inhibit cysteine desulfurase (NFS1) 83 .”
InfluentialRecommendations for robust and reproducible research on ferroptosis
Mishima, E., Nakamura, T., Doll, S., Proneth, B., Fedorova, M., Pratt, D. A., Friedmann Angeli, J. P., Dixon, S. J., Wahida, A., & Conrad, M. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00843-2 · Cited by 163
Regulation of antioxidants in cancer
Hecht, F., Zocchi, M., Alimohammadi, F., & Harris, I. S. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.001 · Cited by 149
Xing, N., Du, Q., Guo, S., Xiang, G., Zhang, Y., Meng, X., Li, X., & Wang, S. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01407-z · Cited by 96
“An anti-cancer drug, Eprenetapopt, inhibits ISC synthesis by inhibiting cysteine desulfurase activity, thereby inducing ferroptosis and limiting cell proliferation [114].”
BackgroundPharmacological reactivation of p53 in the era of precision anticancer medicine
Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 93
Lv, D., Zhong, C., Dixit, D., Yang, K., Wu, Q., Godugu, B., Prager, B. C., Zhao, G., Wang, X., Xie, Q., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.025 · Cited by 91
Metabolic reprogramming in ischemic stroke: when glycolytic overdrive meets lipid storm
Wang, Y., Ge, M., Wang, J., Xu, Y., Wang, N., & Xu, S. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08114-w · Cited by 92
“…adaptations) into a scaffold where amino acids may orchestrate metabolic repair by modulating both glycolytic fl ux (e.g., serine-driven one-carbon metabolism) and lipid peroxidation (e.g., cysteine-dependent glutathione synthesis), though combinatorial targeting studies are needed [186, 206].”
Li, Y., Li, Y., Yu, Y., Ren, X., Yang, C., Jin, W., Li, K., Zhou, Y., Wu, C., Shen, Y., et al. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.06.006 · Cited by 67
Jin, X., Jin, W., Tong, L., Zhao, J., Zhang, L., & Lin, N. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.020 · Cited by 64
“Notably, eprenetapopt (APR-246) is a classical FIN that is under clinical trial, which depletes glutathione with ROS and lipid peroxidation accumulation to trigger ferroptosis in multiple cancer cells 236,237 .”
Ferroptosis in gastrointestinal cancer: from mechanisms to implications
Zhang, R., Kang, R., & Tang, D. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216147 · Cited by 51
Targeting protein disorder: the next hurdle in drug discovery
Lázár, T., Connor, A., DeLisle, C. F., Burger, V., & Tompa, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01220-6 · Cited by 52
“In fact, alternative mechanisms of action have been suggested for YK-4-279, trifluoperazine and the p53 binder eprenetapopt 114 .”
Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and Leukemia
Akiyama, H., Carter, B. Z., Andreeff, M., & Ishizawa, J. (2023) · Cells · doi:10.3390/cells12081128 · Cited by 41
“Frataxin (FXN) [81] and NFS1 cysteine desulfurase [82] are both required for ISC synthesis and are overexpressed in cancer cells.”
BackgroundWang, Q., Li, X., Cao, Z., Feng, W., Chen, Y., & Jiang, D. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c13165 · Cited by 37
Ashoub, M. H., Razavi, R., Heydaryan, K., Salavati‐Niasari, M., & Amiri, M. (2024) · European journal of medical research · doi:10.1186/s40001-024-01822-7 · Cited by 39
“This ferroptosis-inducing effect of APR-246 was later validated in esophageal cancer cell lines, which exhibited an increased turnover of glutathione (GSH) and a suppression of mitochondrial iron–sulfur cluster biosynthesis via NFS1 [217].”
BackgroundOne-carbon metabolism shapes T cell immunity in cancer
Qiu, Y., Xie, E., Xu, H., Cheng, H., & Li, G. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.05.010 · Cited by 36
Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia
Lewis, A. C., Gruber, E., Franich, R. L., Armstrong, J. M., Kelly, M. J., Opazo, C., Low, Y. C., Flippe, L., Wijanarko, K. J., Rowe, C. L., et al. (2025) · Cell · doi:10.1016/j.cell.2025.10.028 · Cited by 41
Self-citationShin, D., Lee, J., & Roh, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216645 · Cited by 39
Zhang, D., Wang, T., Zhou, Y., & Zhang, X. (2023) · Medicine · doi:10.1097/md.0000000000033468 · Cited by 28
“[4–6] It is reported that cell death is tightly involved in tumorigenesis and prognosis.”
Targeting Iron-Sulfur Clusters in Cancer: Opportunities and Challenges for Ferroptosis-Based Therapy
Lee, J., & Roh, J. (2023) · Cancers · doi:10.3390/cancers15102694 · Cited by 34
“Other ISC assembly pharmaceutical inhibitors, eprenetapopt or compound #25, reduce ISC biogenesis, restrict cancer cell proliferation, and trigger ferroptosis by inhibiting NFS1 or ISCA2 [68,78].”
BackgroundInfluentialRegulatory mechanisms of amino acids in ferroptosis
Yao, H., Jiang, W., Liao, X., Wang, D., & Zhu, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122803 · Cited by 33
Epithelial-mesenchymal transition promotes metabolic reprogramming to suppress ferroptosis
Guo, W., Duan, Z., Wu, J., & Zhou, B. P. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.013 · Cited by 38
Hu, W., He, Y., Ren, H., Chai, L., Li, H., Chen, J., Li, C., Wang, Y., & James, T. D. (2024) · Chemical Science · doi:10.1039/d3sc06459j · Cited by 25
She, G., Hai, X.-X., Jia, L.-Y., Zhang, Y., Ren, Y., Pang, Z., Wu, L., Han, M.-Z., Zhang, Y., Li, J., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103597 · Cited by 30
“…ferroptosis, supportive pieces of evidence are also available from studies in cancer cells showing that suppression of NFS1 sensitizes cancer cells to fer-roptosis [22,45], and that patients carrying cancers with high expression of NFS1 were resistant to chemotherapy and had poor survival [23,46].”
Targeting Apoptosis in AML: Where Do We Stand?
Krawiec, K. M., Strzałka, P., Czemerska, M., Wiśnik, A., Zawlik, I., Wierzbowska, A., & Pluta, A. (2022) · Cancers · doi:10.3390/cancers14204995 · Cited by 32
“Eprenetapopt can also induce p53-independent cell death in the course of ferroptosis, a recently described cell death process [113].”
BackgroundDietary Manipulation of Amino Acids for Cancer Therapy
Jiménez‐Alonso, J. J., & López‐Lázaro, M. (2023) · Nutrients · doi:10.3390/nu15132879 · Cited by 26
Lu, C., Qin, C., Wu, J., Jiang, H., Xu, Q., Chen, J., Xu, X., Zhang, X., Guan, M., & Deng, X. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103689 · Cited by 27
Zhang, Y., Gu, Y., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00347-7 · Cited by 30
Wild-type and mutant p53 in cancer-related ferroptosis. A matter of stress management?
Corazzari, M., & Collavin, L. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1148192 · Cited by 23
“Although the pro-ferroptotic action of APR-246 is independent of p53 (Liu et al., 2017; Magri et al., 2021; Fujihara et al., 2022), the drug is a powerful inhibitor of mutant p53 (Hassin and Oren, 2022; Levine, 2022), and this may contribute to its efficacy.”
BackgroundInduction of ferroptosis by natural phenols: A promising strategy for cancer therapy
Zhang, Y., & Xie, J. (2024) · Phytotherapy Research · doi:10.1002/ptr.8149 · Cited by 20
“…involved in pivotal cellular processes like electron transport, DNA synthesis, and mitochondrial respiration, thereby substantiating the cellular functionality and well-being (Fujihara et al., 2022). include research identifying the ferroptotic effects of natural phenols in different cancers.”
BackgroundRole of ferroptosis in esophageal cancer and corresponding immunotherapy
Fan, X., Fan, Y.-T., Zeng, H., Dong, X.-Q., Lu, M., & Zhang, Z. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i7.1105 · Cited by 14
Pottier, C., Montero‐Ruiz, L., Jehay, R., et al. (2025) · 癌症:英文版 · doi:10.1002/cac2.12646 · Cited by 13
“Due to unverified safety of RLS3, we used eprenetapopt (Ep), a p53 activator and GSH depletory [7] proven safe in hematological cancer patients [8].”
Zhang, Y., Liu, X., Xie, L., Hong, J. Y., Zhuang, Q., Ren, L., Li, X., & Zhang, C. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70051 · Cited by 14
“Notably, a previous study suggests that eprenetapopt ‐ mediated inhibition of Nfs1 activity can impede iron – sulphur cluster synthesis, leading to the inhibition of cancer cell proliferation and inducing ferroptosis via eprenetapopt ‐ mediated GSH depletion [26].”
Delineating functional and molecular impact of ex vivo sample handling in precision medicine
Struyf, N., Österroos, A., Vesterlund, M., Arnroth, C., James, T., Sunandar, S., Mermelekas, G., Bohlin, A., Levedahl, K. H., Bengtzén, S., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00528-7 · Cited by 16
“The increased sensitivity of the ferroptosis-inducing agent erastin in frozen samples was linked with decreased p53 protein levels, which is consistent with studies showing the relationship with p53 expression and ferroptosis inhibition 14,15 .”
ResultFighting ischemia-reperfusion injury: Focusing on mitochondria-derived ferroptosis
Tian, L., Liu, Q., Guo, H. W., Zang, H., & Li, Y. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101974 · Cited by 15
Zhang, J., Jia, X., Cao, Q., Chen, Y.-T., Tong, J., Lu, G., Li, D., Han, T., Zhuang, C., & Wang, P. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00406 · Cited by 13
The role of hydrogen sulfide regulation of ferroptosis in different diseases
Lian, J., Chen, Y., Zhang, Y.-T. Y., Guo, S., & Wang, H. (2024) · APOPTOSIS · doi:10.1007/s10495-024-01992-z · Cited by 12
Dong, X.-M., Chen, L., Xu, Y.-X., Wu, P., Xie, T., & Liu, Z. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-024-00858-5 · Cited by 10
“CRISPR perturbation screening revealed that the loss of SHMT2 and MTHFD1L genes signi fi cantly increases the sensitivity of EC cells to Eprenetapopt, thereby enhancing its ef fi cacy in inducing ferrop-tosis in these cells [89].”
Exploring the role of ferroptosis in esophageal cancer: mechanisms and therapeutic implications
Zhao, D., Li, W., Han, Z., Wang, Z., Li, D., & Li, W. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02696-2 · Cited by 13
“Furthermore, the concurrent use of glycine and eprenetapopt effectively restrained the progression of EC and enhanced OS among patients [271].”
InfluentialTargeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status
Mejía-Hernández, J. O., Raghu, D., Caramia, F., Clemons, N. J., Fujihara, K. M., Riseborough, T., Teunisse, A. F. A. S., Jochemsen, A. G., Abrahmsén, L., Blandino, G., et al. (2022) · Cancers · doi:10.3390/cancers14163947 · Cited by 10
“Recent work identified that the small molecule pro-drug eprenetapopt (used interchangeably in our figures as APR-246) promotes ferroptosis in a range of cancer cells [49,50].”
BackgroundSelf-citationA promising new approach to cancer therapy: Manipulate ferroptosis by hijacking endogenous iron
Zhu, L., & Du, Y. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124517 · Cited by 8
Huang, Y., Ding, M., Wang, D., Li, H., Xia, F., Bai, H., Sun, M., Mo, M., Dong, Y., & Shi, L. (2024) · Industrial Crops and Products · doi:10.1016/j.indcrop.2024.118652 · Cited by 10
Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia
Stafylidis, C., Vlachopoulou, D., Kontandreopoulou, C., & Diamantopoulos, P. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041082 · Cited by 6
“Apart from the reported mutant p53 reactivation, preclinical data have also demonstrated that EP results in glutathione depletion and induction of ferroptosis irrespective of TP53 status, thus indicating a different mechanism of action that leads to p53-independent cell death [64,65].”
BackgroundNFS1 Plays a Critical Role in Regulating Ferroptosis Homeostasis
Sun, S., Cao, H., Li, X., & Liao, H. (2025) · Biomolecules · doi:10.3390/biom16010032 · Cited by 7
“Finally, these reseachers found that NFS1 deficiency could increase the intracellular ROS level and induce apoptosis [64].”
Beyond HMAs: Novel Targets and Therapeutic Approaches
Getz, T. M., Bewersdorf, J. P., Kewan, T. Z., Stempel, J. M., Bidikian, A., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.08.001 · Cited by 6
Dietary and nutritional interventions for human diseases: their modulatory effects on ferroptosis
Huang, S., Sun, J. S., Shen, C., & He, G. (2025) · Food & Function · doi:10.1039/d4fo05606j · Cited by 6
Lyu, H., Hou, D., Liu, Y., Wang, J., & Sui, M. (2025) · The FASEB Journal · doi:10.1096/fj.202502544rr · Cited by 5
Zhu, Z., Gan, H., Wang, Y., Jia, G., Li, H., Ma, Z., Wang, J., Shang, X., & Niu, W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062782 · Cited by 4
“Recently, eprenetapopt (APR-246), an anticancer agent targeting mutant p53, was shown to inhibit Fe-S cluster biogenesis by limiting the cysteine desulfurase activity of human NFS1, likely through diminishing the availability of free cysteine by directly conjugating with cysteine [22].”
Pan, Y., Hu, J.-J., Ma, X., et al. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169199 · Cited by 4
TP53 Mutant Acute Myeloid Leukemia: The Immune and Metabolic Perspective
Zingarelli, F., Zannoni, L., & Curti, A. (2022) · Hemato · doi:10.3390/hemato3040050 · Cited by 8
Shah, P. A., Wiman, K. G., Cichowski, K. M., & Rodon, J. A. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473616 · Cited by 5
Ramos, A. D., Liang, Y. Y., Surova, O. V., Bacanu, S., Gerault, M.-A., Mandal, T., Ceder, S., Langebäck, A., Österroos, A., Ward, G. A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114784 · Cited by 6
Pandora’s Box of AML: How TP53 Mutations Defy Therapy and Hint at New Hope
Olesinski, E. A., & Bhatt, S. (2025) · Biomedicines · doi:10.3390/biomedicines13123007 · Cited by 6
“Pre-clinical work indicates that alternative antioxidant or iron-handling pathways may actually blunt eprenetapopt’s activity and contribute to its inefficacy [109].”
Iron and metabolic rewiring in cancer
Ciscar, M., Rodríguez-Santana, C., & Santana-Codina, N. (2026) · Oncogenesis · doi:10.1038/s41389-025-00595-w · Cited by 17
“In fact, a recent study has re-de fi ned eprenetapopt , an anticancer agent that previously failed in phase III clinical trials, as an NFS1 inhibitor that can deplete glutathione to enhance ferroptosis and restrict tumor growth [108].”
Regulatory networks of iron sulfur cluster biology in cancer mechanisms and therapeutic perspectives
Yao, S., Guan, H., Jun, C., & Liu, X. (2026) · iScience · doi:10.1016/j.isci.2026.115256 · Cited by 6
Recent advances in precision medicine for acute myeloid leukemia
Hernández‐Sánchez, A., & Bullinger, L. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000965 · Cited by 4
Zhang, Y., Liu, L., Huang, C., et al. (2025) · Small · doi:10.1002/smll.202503925 · Cited by 3
Mao, Z., Shi, Z., Cui, M., Ma, X., Wang, Y., Zhang, X., Jing, R., & Wang, J. (2025) · Open Life Sciences · doi:10.1515/biol-2025-1135 · Cited by 5
Wu, N., Wang, G., Wang, J., Wu, M., Wang, X., Ma, J., & He, W. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118448 · Cited by 2
Wang, Z., Song, Y., Wang, A., & 刘宝山 (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1795614 · Cited by 5
“At present, several clinical trials, including APR-246, MK-1775, and PRIMA-1, are ongoing, which may offer new hope to patients of NSCLC with TP53 mutation (Fujihara et al., 2022; Kong and Mehanna, 2021; Wang et al., 2023).”
Li, J., Wang, L., Li, Y., Wang, J., Buist‐Homan, M., Faber, K. N., & Moshage, H. J. (2026) · Antioxidants · doi:10.3390/antiox15050552 · Cited by 3
“The roles of GLS1-mediated glu-taminolysis and SHMT2-driven serine metabolism extend to regulating the cellular redox state, as their respective products, glutamate and glycine, are indispensable precursors for the synthesis of the master antioxidant GSH [18,19].”
Sauer, J., Ogger, P. P., Dukic, J., Nessensohn, A., Gabler, S., Schwenzer, A., Unsöld, J. K., Cortès, B. M., Steigenberger, B. A., Perez, N. F., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag146 · Cited by 2
Tret’yakova, E. V., Smirnova, A. A., Babkov, D. A., et al. (2024) · Molecules · doi:10.3390/molecules29153532 · Cited by 2
Frataxin: from the sequence to the biological role
Pignataro, M. F., Noguera, M. E., Herrera, M. G., Román, E. A., & Santos, J. (2025) · Biophysical Reviews · doi:10.1007/s12551-025-01311-z · Cited by 4
“The anticancer agent eprenetapopt inhibits iron-sulfur cluster biogenesis by limiting the cysteine desulfurase activity of NFS1, a fact that potentiates ferroptosis and may restrict cellular proliferation (Fujihara et al. 2022).”
Exosomal non-coding RNA as a key mediator of ferroptosis in lung cancer
Hsu, C., Al-Hasnaawei, S., Kumar, A., et al. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112135 · Cited by 2
Lin, P., Lee, Y., Chen, I.-H., & Chung, H. (2025) · Biomedicines · doi:10.3390/biomedicines13020450 · Cited by 5
“…and Cys277 with methylene quinu-clidinone converted from APR-246 [50], and eprenetapopt (APR-246) inhibits esophageal cellular proliferation and xenograft tumor growth by inducing ferroptosis, inhibiting NFS1 cysteine desulfurase, and synergizing with dietary serine and glycine restriction [51].”
Inhibiting NFS1 by Targeting Liposomes for Combating Cisplatin‐Resistant Colorectal Cancer
Shao, X., Hou, J., Zhang, S., Deng, S., Yang, N., Sun, X., Feng, X., Yin, L., Zhang, T., He, Z., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202519005 · Cited by 3
Yizhu, Z., Mando, Z., Aldurrah, Z., Hanaphi, R. M., Hapiz, A. S. B. A. H., bin Azmi, M. A., Latip, A. S. B. A., Idris, S., Muhamad, A., & Zakaria, F. (2026) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2026.110457 · Cited by 1
Hou, J., Wang, H., Zheng, X., et al. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c03344 · Cited by 1
Cart, J. B., Zhu, D., Norris, L., Piryani, S. O., Chang, L.-C., Eyler, C. E., & Lee, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114974 · Cited by 1
“It has been shown that ARR-246 treatment results in the accumulation of ROS by decreasing intracellular levels of cysteine and GSH [18–20].”
Fundamentals and emerging frontiers in p53-targeted drug development
Long, H.-D., Zhang, N., Wang, W.-E., Ma, Y.-S., Fu-xing, L., Chen, Z.-Y., Lu, C.-N., Wang, X.-F., Han, N., Cai, Y.-F., et al. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102661 · Cited by 2
“Studies have found that the sensitivity of tumor cells to APR-246 depends not only on TP53 mutation status but is also closely related to SLC7A11 expression levels, with SLC7A11 being a better predictive biomarker for efficacy than TP53 mutation status [64].”
Li, J., Cao, Y., Wang, Y., & Shi, H. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.117912 · Cited by 1
Xi, C., Pang, J., Oliaeimotlagh, M., Mao, R., Zhi, W., Jones, K., Hu, T., Shi, H., Ande, S., Horuzsko, A., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09052-x · Cited by 1
Mao, Z., Shi, Z., Cui, M., Ma, X., Wang, Y., Jing, R., & Wang, J. (2023) · Research Square · doi:10.21203/rs.3.rs-3265046/v1 · Cited by 1
Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AMLPreprint
Sinanidis, I., Tsakiroglou, P., Dubner, B. G., Foertsch, R., Gondek, J., Choi, I., Paun, B. C., Zhao, L., Ghiaur, G., & Dalton, W. B. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.13.651470 · Cited by 1
“Treatments with a -SG diet have been tested in solid tumor models (2,14,20,21,31,51–54).”
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’
Peuget, S., & Selivanova, G. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00825-8 · Cited by 1
Inhibition of Heme Biosynthesis Triggers Cuproptosis in Acute Myeloid LeukaemiaPreprint
Lewis, A. C., Gruber, E., Franich, R. L., Armstrong, J. M., Kelly, M. J., Opazo, C., Mawal, C., Birrell, A. M., So, J., Ting, K. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.11.607520
Approaches to anticancer therapy based on modulation of DNA methylation
Павловна, М. В., Makus, J. V., Popova, V. G., Usalka, O., Belitsky, G. A., Геннадиевна, Я. М., & Игоревич, К. К. (2024) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2024-23-4-125-140 · Cited by 1
Progress in research of ferroptosis in gastrointestinal tumors
Chi, Z.-C. (2024) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v32.i10.699
Inhibition of Heme Biosynthesis Triggers Cuproptosis in Acute Myeloid LeukaemiaPreprint
Lewis, A. C., Gruber, E., Franich, R. L., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5159198
Self-citationEfficacy analysis of targeted P53 therapy in solid tumors
Wang, P., & Wang, F. (2025) · Medical Oncology · doi:10.1007/s12032-025-02930-y · Cited by 2
“It can also exert anticancer effects by inducing iron accumulation [71].”
Hou, K., Dong, X., & Niu, W. (2025) · Therapeutic Advances in Hematology · doi:10.1177/20406207251371298 · Cited by 1
“65 Moreover, the developmental landscape of TP53-targeted therapies faces setbacks, with both APR-548 and the CD47 inhibitor magrolimab halting clinical development.”
Kuang, Y., Yang, S., Tian, X., Cheng, H., Liu, B., Zhang, C., Zhang, W., Zhang, W., Zhang, X., & Lou, Y. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218046
Systematic Evaluation Defines the Limits of Ferroptosis in Cancer TherapyPreprint
Fujihara, K. M., Aziz, A., Akbari, B., Gutierrez-Perez, M., Francis, G., Zentout, S., Wu, K., Clemons, N. J., Terzi, E. M., Pacold, M. E., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.11.711115 · Cited by 2
Self-citationZhang, C., Cao, S., Zeng, G., Dong, Y., Li, H., Ma, X., Zhang, X., Li, Z., & Huang, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-44653-8
Terzi, E. M., Fujihara, K. M., Molenaars, M., Biancur, D. E., & Possemato, R. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-03042-w · Cited by 1
“As such, another effect of increasing cellular ferrous iron availability is sensitization to death by ferroptosis [46].”
Self-citationResearch Progress on Targeted Therapeutic Strategies for Mutant p53 in Cancer
罗, 开. (2026) · World Journal of Cancer Research · doi:10.12677/wjcr.2026.162010
Cell state-specific metabolic networks govern ferroptosis versus apoptosis in small cell lung cancerPreprint
Kim, J. W., Bebber, C. M., Dai, Y., Bopp, S., Edenhofer, A., Li, A. M., Rösner, T. N., Berning, L., Yang, M., Leak, L. B., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.27.714827
Ling, H., Qing, L., Zuo, L., Wang, H., Cai, X., Liu, Y., & Tian, H. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168276
Walle, M., Getu, F., Teketelew, B. B., Chane, E., Mola, G., & Berta, D. M. (2026) · Discover Oncology · doi:10.1007/s12672-026-04986-2
“Moreover, Eprenetapopt (APR-246) directly targets mutant TP53 to destabilize it, reducing NRF2/SLC7A11 expression and GSH levels, thereby sensitizing MDS cells to GPX4 dysfunction and inducing ferroptosis [111, 112].”
Liu, Z., Xu, X., Chen, D., Zhang, L., Pan, Y., Liu, D., 沈敏敏, Chen, F., & Chen, M. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05518-z
“Our findings support this role, positioning NFS1 as a key regulator linking mitochondrial function to ferroptotic resistance in colorectal cancer (Liu et al. 2021; Fujihara et al. 2022).”
An, W., Guo, S., Wang, H. J., Lv, T., Wang, W., Li, B., Liu, M., Pu, Y., & Jumuddin, F. A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1887533
Li, M., Huang, C., & Yu, S. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102345
“59 Methionine dependence, or the Hoffman effect, exem-plifies a critical spatial tether in amino acid axes.”
An, X., Wu, D., Wang, Y., Ren, Z., & Yu, W. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01941-6
“Of particular interest is glycine, a precursor of the antioxidant glutathione, which is essential for cellular defense against oxidative stress and ferroptosis (Ling et al. 2022; Fujihara et al. 2022).”
Wang, C.-L., Lv, J.-T., Liu, S.-J., Zhang, Y., Wang, S.-L., & Song, S.-Q. (2026) · BBA Advances · doi:10.1016/j.bbadva.2026.100199 · Cited by 1
“The second centers on the FDX1 – LIAS – lipoylation axis, leveraging the enhanced mitochondrial dependency induced by ARSIs to amplify susceptibility to cuproptosis [88 – 89].”
Zhao, A., Li, R., Liang, R., Zhuang, Q., Liu, Y., Deng, D., Yu, P., Peng, L., Xu, H., Zhang, J., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.181465 · Cited by 1
The Methionine-Mitochondria Axis in Cancer: Metabolic Cross-Talk and Therapeutic Vulnerabilities
Shakil, M. S., & McBride, M. J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00481-y
“1 cells, indicating reduced TCA activity and energy production [41].”
Metabolites and cancer metastasis
Yang, S., Shi, S., Hou, J., Zhang, J., & Su, Z. (2026) · Oncogene · doi:10.1038/s41388-026-03930-6
Metadata
- Authors
- Fujihara, K. M., Zhang, B. Z., Jackson, T. D., Ogunkola, M. O., Nijagal, B., Milne, J. V., Sallman, D. A., Ang, C.-S., Nikolic, I., Kearney, C. J., Hogg, S. J., Cabalag, C. S., Sutton, V. R., Watt, S., Fujihara, A. T., Trapani, J. A., Simpson, K. J., Stojanovski, D., Leimkühler, S., Haupt, S., Phillips, W. A., & Clemons, N. J.
- Affiliations
- The University of Melbourne (AU)
- University of Potsdam (DE)
- Moffitt Cancer Center (US)
- Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Memorial Sloan Kettering Cancer Center (US)
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Fujihara, Kenji M.
- Clemons, Nicholas J.
- ORCID
- Fujihara, Kenji M.
- Jackson, Thomas D.
- Ogunkola, Moses O.
- Nijagal, Brunda
- Milne, Julia V.
- Sallman, David A.
- Ang, Ching-Seng
- Kearney, Conor J.
- Hogg, Simon J.
- Cabalag, Carlos S.
- Sutton, Vivien R.
- Fujihara, Asuka T.
- Trapani, Joseph A.
- Simpson, Kaylene J.
- Stojanovski, Diana
- Leimkühler, Silke
- Haupt, Sue
- Phillips, Wayne A.
- Clemons, Nicholas J.
- Venue
- Science Advances
- Published
- 2022-09-16
- Volume
- 8
- Issue
- 37
- Pages
- eabm9427-eabm9427
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC9473576
- OpenAlex
- W4295900094
- Cited by
- 102
- References
- 58
- Citations by year
- 2026: 30 · 2025: 30 · 2024: 24 · 2023: 15 · 2022: 3
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Science Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- publish.UP (University of Potsdam) (submittedVersion, cc-by)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Sulfur Compounds in Biology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- APR-246, ferroptosis, glutathione depletion, glutathione synthesis, iron-sulfur cluster assembly, NFS1, cysteine desulfurase, dietary restriction, esophageal cancer, SLC7A11, SHMT2, MTHFD1L, GCLC, GCLM, tumor growth inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.